Clinical Trial Update: Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in Children [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the combination of Darafenib or Trametinib with Clofarabine for high-risk, recurrent, or refractory Langerhans cell histi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Langerhans Cell Histiocytosis

Drugs mentioned

• Clofarabine (clofarabine)
• Darafenib (darafenib)
• Trametinib (trametinib)

Snippet

Sponsor: West China Second University Hospital | Conditions: Langerhans Cell Histiocytosis (LCH) | Phase 2 | Status: RECRUITING